Ruffini教授：在肺癌等胸部恶性肿瘤研究成果令人振奋的背景下，2025 ELCC聚焦三大胸部肿瘤：肺癌、胸腺肿瘤和胸膜间皮瘤。对于每一种肿瘤，胸外科手术都能发挥重要作用。

 

在肺癌领域，通过综合治疗手段的应用（如新辅助化疗联合免疫、辅助治疗及围手术治疗），手术在分期更晚的肺癌中的角色出现改变，我们正在探索挽救性手术，也就是完成根治性放化疗和免疫治疗后的手术治疗。外科手术始终在肺癌治疗中占据重要地位，如今我们拥有更多的手术技术和设备，能够为患者提供安全性极高的手术，并缩短术后恢复时间，然后接受后续辅助免疫治疗和/或辅助化疗。我很高兴在2025 ELCC看到众多中国学者的研究成果展示，也结识了许多中国同行。你们确实处于胸外科发展的最前沿，所做的卓越工作有目共睹。我在欧美多个学术会议上都能看到中国胸外科同行的杰出成果。我们就像一个团结的大家庭，构建这样的学术共同体至关重要。目前有各种便捷沟通工具可实现跨国交流，每次通过Zoom会议（尽管要克服时差）与中国同行交流都让我倍感愉悦，与美国同行的合作也是如此。

 

在胸膜间皮瘤领域，我们正在通过新的MARS2临床试验重新探讨手术的价值。根据2025 ELCC“间皮瘤治疗更新”教育专场的讨论，手术仍可在胸膜间皮瘤治疗中发挥作用。

 

对于胸腺肿瘤，手术在所有分期胸腺瘤治疗中占据不可争议的地位，但成功的核心仍在于多学科协作——需要肿瘤内科、放疗科、病理科和呼吸科专家共同参与决策。如果各大洲、各国之间缺乏这样的学术交流，我们就无法取得任何实质性的进展。

 

周教授：完全同意。外科始终是胸部肿瘤治疗的核心和基石，无论是肺癌、胸腺瘤抑或胸膜间皮瘤。我们肿瘤内科医生需要与外科团队及多学科同仁紧密协作，通过多学科诊疗模式提升患者的临床治愈率，有效改写癌症的自然转归。

 

Dr.Ruffini:Thank you for the question.I think that we are living in a really exciting period in the research about lung cancer，and for thoracic malignancies as well.So，I would like to extend the concept.This Conference was designed for three thoracic cancers–lung cancer，thymic tumors and pleural mesothelioma.For each of these，I think thoracic surgery can play a great role.

 

Now，with the use of integrated treatment，like chemo-IO，plus adjuvant and perioperative strategies，this has really changed the scenario of the role of surgery in the more advanced disease.We are now talking about salvage surgery，meaning surgery after definitive chemo-，radio-and immunotherapy.Surgery continues to have a role in the treatment of lung cancer.As I said at the beginning of this interview，we now have much more technology，more tools and more devices to provide these patients with a very safe surgery with a short post-operative period in order for them to recover quickly，in order to get access to adjuvant immunotherapy and/or adjuvant chemotherapy.This is a major step forward for thoracic surgery.I was very glad to see a lot of Chinese posters here，I know many Chinese colleagues.You are really in the frontline of thoracic surgery advances.You are doing a fantastic job.I can see the results of my thoracic surgery colleagues at many conferences across the United States and Europe.So，we are a big family，all together.It is important to have this big community.We have all the tools to communicate.We have Zoom calls.Sometimes you are very early in the morning and sometimes you are in the middle of the night.Sometimes we are in the middle of the night.But it is fun.Every time I communicate with my Chinese colleagues，I am very happy.It is the same for my US colleagues and so on.This is for lung cancer.

 

For pleural mesothelioma，we are now discussing the role of surgery，which was entered into the discussion with the new MARS2 trial.This morning，we discussed that surgery can still have a role in pleural mesothelioma.Finally，for thymic tumors，surgery has an indisputable role across all stages of disease，but once again，the key to this success is the multidisciplinary approach，for the medical oncologist，the radiation oncologist，pathologist，pulmonologist to talk together.This is the key.If there is no communication between us，between continents and between countries，then we are not progressing anywhere.

 

Dr.Zhou:I totally agree.More and more，surgery is at the center of the treatment of thoracic cancer–lung cancer，thymic tumors and mesothelioma.We need surgery.We are a team.As a team，we should work together.We should communicate together.In that way，we can improve the cure rate for our patients.We can change the natural history of cancer.We should work together.Thank you very much.

 

《肿瘤瞭望》在ELCC现场报道